MI-Heart Ceramides, Plasma
Use
The MI-Heart Ceramides test is used to evaluate the risk of major adverse cardiovascular events within the next 1 to 5 years. Plasma ceramides are predictors of myocardial infarction, coronary revascularization, acute coronary syndrome hospitalization, and mortality within 5 years. The risk conferred by plasma ceramides is independent of common cholesterol levels and inflammatory markers, and they can be reduced through diet, exercise, and certain medications. This test is therefore useful in identifying individuals at elevated risk who may benefit from preventive strategies.
Special Instructions
Patients should not be receiving Intralipid, as it may cause false elevations in ceramides. If not ordering electronically, a Cardiovascular Test Request Form (T724) should be completed and sent with the specimen.
Limitations
This test was developed by Mayo Clinic and determined its performance characteristics consistent with CLIA requirements, but it has not been cleared or approved by the FDA. Factors affecting ceramide levels not accounted for could include metabolic dysfunction, dyslipidemia, and improper specimen handling. Lower age reference values are not established for patients under 18 years of age.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 93883-7
- 93882-9
- 93881-1
- 93880-3
- 93879-5
- 93878-7
- 93877-9
- 93876-1
Result Turnaround Time
2-7 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Lavender top (EDTA)
Collection Instructions
Centrifuge, aliquot at least 1 mL of plasma into a plastic vial and freeze within 8 hours.
Patient Preparation
Patients should not be receiving Intralipid because it may cause false elevations in measured ceramides.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 24 hours |
| Frozen | 30 days |